Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Hepatocellular 4Stomach Neoplasms 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Breast Neoplasms 3Spinocerebellar Degenerations 2Recurrence 2Rectal Neoplasms 2Neoplasms 2Gastric / Gastroesophageal Junction Adenocarcinoma 2EBV-associated Tumors 2Carcinoma, Non-Small-Cell Lung 2Vascular Complications 1Triple Negative Breast Neoplasms 1Solid Tumors 1Solid Cancers 1Small Cell Lung Carcinoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Pancreatic Cancer Metastatic 1Oropharyngeal Neoplasms 1Nasopharyngeal Cancinoma (NPC) 1Mouth Neoplasms 1Melanoma 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Head and Neck Neoplasms 1Gynecologic Cancers 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

Cyclophosphamide 6fludarabine 5Rituximab 4obinutuzumab 3tafasitamab 2relmacabtagene autoleucel 2pirtobrutinib 2zanubrutinib 1venetoclax 1tisagenlecleucel 1resiniferatoxin 1pomalidomide 1polatuzumab vedotin 1glofitamab 1Vincristine 1Tretinoin 1Surveys and Questionnaires 1Specimen Handling 1Radiotherapy 1Prednisolone 1Magnetic Resonance Spectroscopy 1Interleukin-2 1Immunotherapy, Adoptive 1Immune Checkpoint Inhibitors 1Doxorubicin 1Dexamethasone 1Blood Specimen Collection 1Bendamustine Hydrochloride 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma, B-Cell × Immune Checkpoint Inhibitors × Clear all
NCT06646666 2024-11-01

ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT

Ruijin Hospital

Phase 2 Not yet recruiting
35 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡